News Sentiment

IOVA sentiment intelligence

Iovance Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.23 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.9% over one week, +3.7% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend active 3.7% over four weeks
Fair value -28.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 32
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 9
simplywall.st 6
Sahm 3
Insider Monkey 3
Stock Titan 3
Ad Hoc News 3
TechStock² 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 18
Regulatory and legal 8
Analyst action 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
TechStock² Direct company coverage

Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value

Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18.2% on Wednesday without new company news, suggesting a repricing of existing information. This jump added approximately $319 million to its market value, nearly matching its March 31 cash position. The rally is likely linked

Tone
Positive 66/100
Event
Balance sheet
Published
15 Jul 2026 15:08
Source
TechStock²
StocksToTrade Direct company coverage

IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up

Iovance Biotherapeutics (IOVA) stock is showing an 8.14% increase due to optimism surrounding new cancer therapy developments. The company has filed for a mixed securities shelf to allow flexible capital raises and has granted inducement stock options to 27 new non-executive empl

Tone
Positive 66/100
Event
Market update
Published
15 Jul 2026 12:33
Source
StocksToTrade
Sahm Direct company coverage

Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative

Iovance Biotherapeutics (IOVA) has recently refreshed its corporate presentation, leading to significant share price momentum. Despite this, a valuation analysis suggests the stock could be 76% undervalued, with a fair value of $18 compared to its current price of $4.37. The pote

Tone
Positive 73/100
Event
Market update
Published
11 Jul 2026 13:40
Source
Sahm
Stock Titan Direct company coverage

Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028

Iovance Biotherapeutics has updated its corporate outlook, projecting Q2 2026 revenue of $86M–$88M and full-year 2026 revenue of $350M–$370M, with a cash runway extending into 2028. The company highlights the commercial progress of Amtagvi, its FDA-approved T cell therapy for adv

Tone
Positive 70/100
Event
Earnings
Published
03 Jul 2026 20:39
Source
Stock Titan
Simply Wall Street Direct company coverage

IOVA - Why I think Iovance is undervalued

The author believes Iovance Biotherapeutics (IOVA) is undervalued, with the market focusing on past setbacks rather than future potential. They highlight the approval of Amtagvi, a TIL therapy, and improving commercial performance, expecting strong revenue growth in 2026. The art

Tone
Positive 70/100
Event
Earnings
Published
03 Jul 2026 08:39
Source
Simply Wall Street
The National Law Review Direct company coverage

Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi

Levi & Korsinsky LLP has filed a class action securities lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) for alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth potential, failing

Tone
Negative 27/100
Event
Regulatory and legal
Published
03 Jul 2026 02:40
Source
The National Law Review
TradingView Direct company coverage

Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance

Iovance Biotherapeutics has updated its corporate presentation, reaffirming its revenue guidance for FY2026 at $350M–$370M and Q2 2026 guidance at $86M–$88M. The company reported a cash balance of $319M as of March 31, 2026, with a runway extending into 2028. Key highlights inclu

Tone
Positive 65/100
Event
Earnings
Published
02 Jul 2026 20:39
Source
TradingView
Finviz Direct company coverage

IOVA - Iovance Biotherapeutics Inc Options

This article provides a detailed financial overview of Iovance Biotherapeutics Inc. (IOVA), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation, profitability, growt

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 14:39
Source
Finviz
GuruFocus Direct company coverage

Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript

This article provides the transcript from the Iovance Biotherapeutics Inc Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually, with Chairman Ian Dukes presiding and key officers like Colleen Roche (CFO) and Fred Boit (Interim CEO, President, and

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 13:13
Source
GuruFocus
TradingView Direct company coverage

Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB

This article provides financial information for Iovance Biotherapeutics Inc. It displays the enterprise value to revenue forward for the company, accessible through its listing on the Stuttgart Stock Exchange under the ticker 2LB. The content is primarily a data page from Trading

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – SWB:2LB

The article provides a single financial metric for Iovance Biotherapeutics Inc (SWB:2LB) on the Stuttgart Stock Exchange: its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded at the time of publication. The content primarily focuse

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA

This article provides financial information for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), specifically focusing on its forward price-to-sales ratio. It briefly mentions real-time market data providers and copyright information related to financial data. The content is present

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Iovance Biotherapeutics Inc – LS:A2DT49

This article provides financial data for Iovance Biotherapeutics Inc (LS:A2DT49), specifically focusing on its forward price-to-sales ratio. It appears to be a section from a financial data platform, likely TradingView, showing stock information and navigational links related to

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:39
Source
TradingView
TradingView Direct company coverage

Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA)

This article provides an overview of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) including its current stock price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, an upcoming earnings report, and past earnings an

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Iovance Biotherapeutics Inc – LS:A2DT49

This page provides financial data specifically on the "Price to earnings forward" metric for Iovance Biotherapeutics Inc (LS:A2DT49) from TradingView. The article indicates the market is closed for this stock and presents the data under its financial overview section.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView
Sahm Direct company coverage

Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma

Iovance Biotherapeutics (IOVA) has received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma, marking its third market authorization after the US and Canada. This approval expands the company's geographic reach and potential revenue streams,

Tone
Positive 73/100
Event
Earnings
Published
25 Jun 2026 12:39
Source
Sahm
Market source Direct company coverage

Iovance (IOVA) Surges 9.4% on Regulatory Nod

Iovance Biotherapeutics Inc. (IOVA) saw its share price surge by 9.4% after securing conditional approval from Australia's Therapeutic Goods Administration (TGA) for Amtagvi, its tumor-derived T-cell immunotherapy, for advanced melanoma. This marks the company's third marketing a

Tone
Positive 92/100
Event
Regulatory and legal
Published
24 Jun 2026 04:39
Source
Market source
StocksToTrade Direct company coverage

IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands

Iovance Biotherapeutics Inc. (IOVA) stock climbed by 8.5% following the conditional approval of its cancer therapy, Amtagvi, in Australia for advanced melanoma. This marks its third global marketing authorization and first T-cell therapy for solid tumors in that market. Additiona

Tone
Positive 74/100
Event
Regulatory and legal
Published
23 Jun 2026 16:11
Source
StocksToTrade
TradingKey Direct company coverage

Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Iovance Biotherapeutics Inc (IOVA), noting its current price momentum score of 6.95 and its trading range between a resistance level of $4.53 and a support level of $3.64. It details various technical indicators like MACD, RSI, and mo

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 03:10
Source
TradingKey
Sahm Direct company coverage

Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings

Iovance Biotherapeutics (IOVA) recently filed new shelf registrations, providing flexibility for future capital raising and employee incentives. Despite some short-term share price softening, the company has seen strong longer-term momentum with significant year-to-date and 1-yea

Tone
Positive 65/100
Event
Market update
Published
22 Jun 2026 23:10
Source
Sahm
www.marketscreener.com Direct company coverage

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 140,860 shares of its common stock to twenty-seven new, non-executive employees on June 18, 2026. These awards were made under Iovance's Amended and Restated 2021 Inducement Plan in accordance

Tone
Positive 60/100
Event
Market update
Published
22 Jun 2026 14:10
Source
www.marketscreener.com
Pluang Direct company coverage

Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules.

Iovance Biotherapeutics has approved inducement stock options for 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91 and a three-year vesting period. This move complies with Nasdaq Listing Rule 5635(c)(4) and is intended to promote employee retentio

Tone
Positive 66/100
Event
Market update
Published
19 Jun 2026 21:41
Source
Pluang
Quiver Quantitative Direct company coverage

Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees

Iovance Biotherapeutics has granted inducement stock options covering 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91, the closing price on June 18, 2026. These options vest over three years and are part of the company's Amended and Restated 2021

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 21:20
Source
Quiver Quantitative